Entrada Therapeutics, Inc. TRDA
6.16
(0.06)
(0.96%)
as of 25 Sep
- Market cap
- $242.2M
- P/E
- 0.0×
Follow TRDA
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(27.11%) | (39.13%) | (48.28%) | (54.09%) | |
| (21.39%) | (31.81%) | (40.42%) | (44.35%) | ||
ROIC |
(547.44%) | (1,009.37%) | (697.14%) | (1,060.24%) | |
Return on Tangible Assets |
(32.06%) | (49.72%) | (65.35%) | (76.38%) | |
Average Days of Receivables |
7.10 | 16.90 | 50.06 | 63.56 | |
Free Cash Flow per Share |
(3.13) | (3.13) | (3.15) | (3.18) | |
Free Cash Flow |
(129.80) | (129.55) | (131.64) | (134.35) | |
Capital Expenditures |
(1.88) | (1.04) | 0.06 | 0.32 | |
Piotroski F-Score |
1.00 | 2.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(19.16%) | (21.33%) | (25.05%) | (29.51%) | |
Accounts Receivable Turnover |
32.39 | 10.47 | 4.05 | 4.70 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.03) | (0.01) | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
230.36% | 559.65% | 2,496.50% | 3,003.44% | |
Selling, General and Administrative Expense of Revenue |
67.23% | 161.48% | 712.79% | 863.64% | |
Share Based Compensation of Revenue |
32.43% | 77.14% | 335.76% | 413.32% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.24 | 0.89 | 0.79 | 0.81 | |
Depreciation/Fixed assets |
(0.16) | 0.06 | 0.17 | 0.24 | |
Capex/Depreciation |
1.40 | (2.45) | 0.05 | 0.23 | |
Revenue per Share |
1.48 | 0.61 | 0.14 | 0.11 | |
Operating CF per Share |
(3.08) | (3.11) | (3.15) | (3.19) | |
Capex per Share |
(0.05) | (0.03) | 0.00 | 0.01 | |
Capex to Sales |
0.03 | 0.04 | (0.01) | (0.07) | |
Net Profit Margin |
(168.16%) | (565.48%) | (2,895.05%) | (3,537.73%) |
Columns are period end dates